<DOC>
	<DOCNO>NCT01103622</DOCNO>
	<brief_summary>The purpose study determine whether AZD1656 affect pharmacokinetics ( PK ) digoxin type 2 diabetes mellitus ( T2DM ) patient .</brief_summary>
	<brief_title>Investigate Effect AZD1656 Pharmacokinetics Digoxin Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>Patients confirm type 2 diabetes least 1 year treat metformin single treatment combination one oral anti diabetic least 2 month prior screen . Body mass index ≥19 ≤42 kg/m2 . Haemoglobin ( Hb ) A1c ≥6.5 % ≤9.5 % enrolment . History cardiovascular disease , eg , leave ventricular hypertrophy , uncontrolled hypertension , paroxysmal persistent cardiac arrhythmia ischemic heart disease . Systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 95 mmHg screening Use amiodarone within 3 month prior screen use potent CYP450 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2</keyword>
	<keyword>Digoxin</keyword>
	<keyword>drug-drug interaction</keyword>
</DOC>